A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Inclusion Criteria:
Exclusion Criteria:
Ciudad de Buenos Aires, C1431, Argentina
Ciudad de San Miguel de Tucuman, T4000AXL, Argentina
South Woodville, 5011, Australia
Karvina Frystat, 73301, Czechia
Itabashi Ku, 173 8606, Japan
Kita Gun, 761 0793, Japan
Osaka, 550 0006, Japan
Krakow, 30-002, Poland